JP2011505812A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011505812A5 JP2011505812A5 JP2010537317A JP2010537317A JP2011505812A5 JP 2011505812 A5 JP2011505812 A5 JP 2011505812A5 JP 2010537317 A JP2010537317 A JP 2010537317A JP 2010537317 A JP2010537317 A JP 2010537317A JP 2011505812 A5 JP2011505812 A5 JP 2011505812A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- group
- sequence
- complementary
- stringent conditions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 15
- 230000003321 amplification Effects 0.000 claims 9
- 238000003199 nucleic acid amplification method Methods 0.000 claims 9
- 230000000295 complement effect Effects 0.000 claims 8
- 108020004414 DNA Proteins 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 6
- 230000011987 methylation Effects 0.000 claims 6
- 238000007069 methylation reaction Methods 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 239000002773 nucleotide Substances 0.000 claims 6
- 125000003729 nucleotide group Chemical group 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 5
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims 4
- 239000012472 biological sample Substances 0.000 claims 4
- 239000003153 chemical reaction reagent Substances 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 230000002062 proliferating effect Effects 0.000 claims 4
- 108091029430 CpG site Proteins 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 108091034117 Oligonucleotide Proteins 0.000 claims 3
- 108091093037 Peptide nucleic acid Proteins 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 108090000790 Enzymes Proteins 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 108010076804 DNA Restriction Enzymes Proteins 0.000 claims 1
- 206010061818 Disease progression Diseases 0.000 claims 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims 1
- 235000011130 ammonium sulphate Nutrition 0.000 claims 1
- 238000001574 biopsy Methods 0.000 claims 1
- 210000000601 blood cell Anatomy 0.000 claims 1
- 210000001124 body fluid Anatomy 0.000 claims 1
- 239000010839 body fluid Substances 0.000 claims 1
- 230000009702 cancer cell proliferation Effects 0.000 claims 1
- 208000035269 cancer or benign tumor Diseases 0.000 claims 1
- 238000012512 characterization method Methods 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- ZZTURJAZCMUWEP-UHFFFAOYSA-N diaminomethylideneazanium;hydrogen sulfate Chemical compound NC(N)=N.OS(O)(=O)=O ZZTURJAZCMUWEP-UHFFFAOYSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 230000005750 disease progression Effects 0.000 claims 1
- 238000009396 hybridization Methods 0.000 claims 1
- 229940079826 hydrogen sulfite Drugs 0.000 claims 1
- 230000006607 hypermethylation Effects 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 108091008146 restriction endonucleases Proteins 0.000 claims 1
- 238000012163 sequencing technique Methods 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07122844.9 | 2007-12-11 | ||
| EP07122844 | 2007-12-11 | ||
| EP08150557 | 2008-01-23 | ||
| EP08150557.0 | 2008-01-23 | ||
| PCT/EP2008/010549 WO2009074328A2 (en) | 2007-12-11 | 2008-12-11 | Methods and nucleic acids for analyses of lung carcinoma |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011505812A JP2011505812A (ja) | 2011-03-03 |
| JP2011505812A5 true JP2011505812A5 (OSRAM) | 2013-01-24 |
| JP5694776B2 JP5694776B2 (ja) | 2015-04-01 |
Family
ID=40362005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010537317A Expired - Fee Related JP5694776B2 (ja) | 2007-12-11 | 2008-12-11 | 細胞増殖性障害の解析のための方法及び核酸 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20110003292A1 (OSRAM) |
| EP (2) | EP2229456A2 (OSRAM) |
| JP (1) | JP5694776B2 (OSRAM) |
| AU (1) | AU2008334901A1 (OSRAM) |
| CA (1) | CA2708163A1 (OSRAM) |
| WO (1) | WO2009074328A2 (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110171637A1 (en) * | 2006-07-21 | 2011-07-14 | Reimo Tetzner | Methods and nucleic acids for analyses of cellular proliferative disorders |
| CA2670144A1 (en) | 2006-11-24 | 2008-05-29 | Epigenomics Ag | Methods and nucleic acids for the analysis of gene expression associated with the development of prostate cell proliferative disorders |
| GB0823445D0 (en) * | 2008-12-23 | 2009-01-28 | Univ Surrey | Biomarker |
| GB0912175D0 (en) * | 2009-07-13 | 2009-08-26 | Univ Surrey | Biomarker |
| GB0912190D0 (en) * | 2009-07-13 | 2009-08-26 | Univ Surrey | Biomarker |
| US20120157324A1 (en) * | 2009-08-17 | 2012-06-21 | Yale University | Methylation biomarkers and methods of use |
| US20110104695A1 (en) * | 2009-11-05 | 2011-05-05 | Epigenomics Ag | Methods of predicting therapeutic efficacy of cancer therapy |
| CA3111723A1 (en) * | 2012-01-30 | 2013-08-08 | Exact Sciences Development Company, Llc | Sulfonated small dna compositions and methods for sulfonating and desulfonating small dnas |
| AU2013337915A1 (en) * | 2012-10-31 | 2015-05-21 | Becton, Dickinson And Company | Selective amplification and real-time PCR detection of rare mutations |
| JP2014161308A (ja) * | 2013-02-27 | 2014-09-08 | St Marianna Univ School Of Medicine | 胃癌の検出又は胃癌発症のリスク評価のための指標を得る方法 |
| US10385406B2 (en) * | 2016-05-05 | 2019-08-20 | Exact Sciences Development Company, Llc | Detection of lung neoplasia by analysis of methylated DNA |
| WO2020240511A1 (en) * | 2019-05-29 | 2020-12-03 | Hkg Epitherapeutics Limited | Epiaging: novel ecosystem for managing healthy aging |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585481A (en) | 1987-09-21 | 1996-12-17 | Gen-Probe Incorporated | Linking reagents for nucleotide probes |
| US5457183A (en) | 1989-03-06 | 1995-10-10 | Board Of Regents, The University Of Texas System | Hydroxylated texaphyrins |
| US5245022A (en) | 1990-08-03 | 1993-09-14 | Sterling Drug, Inc. | Exonuclease resistant terminally substituted oligonucleotides |
| US5565552A (en) | 1992-01-21 | 1996-10-15 | Pharmacyclics, Inc. | Method of expanded porphyrin-oligonucleotide conjugate synthesis |
| US5574142A (en) | 1992-12-15 | 1996-11-12 | Microprobe Corporation | Peptide linkers for improved oligonucleotide delivery |
| SE501439C2 (sv) | 1993-06-22 | 1995-02-13 | Pharmacia Lkb Biotech | Sätt och anordning för analys av polynukleotidsekvenser |
| WO1995015373A2 (en) | 1993-11-30 | 1995-06-08 | Mcgill University | Inhibition of dna methyltransferase |
| US5597696A (en) | 1994-07-18 | 1997-01-28 | Becton Dickinson And Company | Covalent cyanine dye oligonucleotide conjugates |
| US5514758A (en) | 1994-09-30 | 1996-05-07 | The Goodyear Tire & Rubber Company | Process for making latex for high performance masking tape |
| US5786146A (en) | 1996-06-03 | 1998-07-28 | The Johns Hopkins University School Of Medicine | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
| US6017704A (en) | 1996-06-03 | 2000-01-25 | The Johns Hopkins University School Of Medicine | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
| US5912264A (en) | 1997-03-03 | 1999-06-15 | Bristol-Myers Squibb Company | 6-halo-or nitrate-substituted paclitaxels |
| US6251594B1 (en) | 1997-06-09 | 2001-06-26 | Usc/Norris Comprehensive Cancer Ctr. | Cancer diagnostic method based upon DNA methylation differences |
| DE19754482A1 (de) | 1997-11-27 | 1999-07-01 | Epigenomics Gmbh | Verfahren zur Herstellung komplexer DNA-Methylierungs-Fingerabdrücke |
| US7700324B1 (en) | 1998-11-03 | 2010-04-20 | The Johns Hopkins University School Of Medicine | Methylated CpG island amplification (MCA) |
| US5958773A (en) | 1998-12-17 | 1999-09-28 | Isis Pharmaceuticals Inc. | Antisense modulation of AKT-1 expression |
| US6331393B1 (en) | 1999-05-14 | 2001-12-18 | University Of Southern California | Process for high-throughput DNA methylation analysis |
| JP2005512499A (ja) * | 2000-09-01 | 2005-05-12 | エピゲノミクス アーゲー | 進行中の疾病または特定の疾病の発病素質の診断 |
| US20050235375A1 (en) * | 2001-06-22 | 2005-10-20 | Wenqiong Chen | Transcription factors of cereals |
| US7473767B2 (en) | 2001-07-03 | 2009-01-06 | The Institute For Systems Biology | Methods for detection and quantification of analytes in complex mixtures |
| DE10338308B4 (de) | 2003-08-15 | 2006-10-19 | Epigenomics Ag | Verfahren zum Nachweis von Cytosin-Methylierungen in DNA |
| EP1769086A2 (en) * | 2004-07-18 | 2007-04-04 | Epigenomics AG | Epigenetic methods and nucleic acids for the detection of breast cell proliferative disorders |
| JP2008521412A (ja) * | 2004-11-30 | 2008-06-26 | ベリデックス・エルエルシー | 肺癌予後判定手段 |
| EP2280084B1 (en) * | 2004-12-02 | 2015-02-11 | Epigenomics AG | Methods and nucleic acids for the analysis of gene expression associated with the prognosis of prostate cell proliferative disorders |
| CN114921544A (zh) * | 2005-04-15 | 2022-08-19 | Epi基因组股份公司 | 分析细胞增殖性病症的方法和核酸 |
| WO2006128140A2 (en) * | 2005-05-27 | 2006-11-30 | Dana-Farber Cancer Institute, Inc. | Gene methylation and expression |
| NZ569697A (en) * | 2006-01-20 | 2012-01-12 | Women S & Children S Health Res Inst | Method of treatment, prophylaxis and diagnosis of pathologies of the bone by the modulation of GPC3 |
| WO2007085497A2 (en) * | 2006-01-30 | 2007-08-02 | Epigenomics Ag | Markers for the prediction of outcome of anthracycline treatment |
| ATE508207T1 (de) * | 2006-02-28 | 2011-05-15 | Charite Universitaetsmedizin | Nachweis und qualitätskontrolle von regulator-t- zellen mittels dna-methylierungsanalyse des foxp3-gens |
| EP2046994A4 (en) * | 2006-07-14 | 2010-04-14 | Univ Johns Hopkins | EARLY DETECTION AND FORECAST OF DARM CARCINOMAS |
| US20090203011A1 (en) * | 2007-01-19 | 2009-08-13 | Epigenomics Ag | Methods and nucleic acids for analyses of cell proliferative disorders |
| SI2258871T1 (sl) * | 2007-01-19 | 2014-09-30 | Epigenomics Ag Intellectual Property | Postopki in nukleinske kisline za analize celičnih proliferativnih motenj |
| JP2010517582A (ja) * | 2007-02-12 | 2010-05-27 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 結腸癌の早期検出および予後診断の方法 |
| JP2008212009A (ja) * | 2007-02-28 | 2008-09-18 | Sysmex Corp | Ｄｎａメチル化検出用試料の調製方法 |
| EP2525651A4 (en) * | 2010-01-22 | 2013-12-11 | Chromatin Inc | NEW CENTROMERE AND METHOD FOR THEIR USE |
-
2008
- 2008-12-11 AU AU2008334901A patent/AU2008334901A1/en not_active Abandoned
- 2008-12-11 US US12/747,584 patent/US20110003292A1/en not_active Abandoned
- 2008-12-11 EP EP08860719A patent/EP2229456A2/en not_active Withdrawn
- 2008-12-11 EP EP10008955A patent/EP2302069A1/en not_active Withdrawn
- 2008-12-11 CA CA2708163A patent/CA2708163A1/en not_active Abandoned
- 2008-12-11 JP JP2010537317A patent/JP5694776B2/ja not_active Expired - Fee Related
- 2008-12-11 WO PCT/EP2008/010549 patent/WO2009074328A2/en not_active Ceased
-
2015
- 2015-12-22 US US14/978,642 patent/US20160194722A1/en not_active Abandoned
-
2017
- 2017-08-09 US US15/672,858 patent/US20180023144A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011505812A5 (OSRAM) | ||
| CN110872631B (zh) | Dna甲基化生物标志物组合、检测方法和试剂盒 | |
| JP6722659B2 (ja) | 結腸直腸癌のためのメチル化マーカー | |
| JP2009533066A5 (OSRAM) | ||
| US10266900B2 (en) | Method for detecting precancerous lesions | |
| JP2010516234A5 (OSRAM) | ||
| EP3083993B1 (en) | Gene methylation based colorectal cancer diagnosis | |
| JP2008506407A5 (OSRAM) | ||
| CN113186278B (zh) | 甲状腺结节良恶性相关标志物及其应用 | |
| WO2018069450A1 (en) | Methylation biomarkers for lung cancer | |
| JPWO2020112869A5 (OSRAM) | ||
| CN119421958A (zh) | 鉴别癌症的甲基化标志物及应用 | |
| CN113122631A (zh) | 检测dna甲基化的试剂及用途 | |
| US20150299809A1 (en) | Biomarkers for Clinical Cancer Management | |
| JP5258760B2 (ja) | メチル化核酸又は非メチル化核酸を増幅する方法 | |
| US20250002987A1 (en) | Detection of methylation status of a dna sample | |
| CN117448450A (zh) | 用于结直肠癌筛查的标志物、探针组合物及其应用 | |
| CN118451202A (zh) | 一种肿瘤检测方法及应用 | |
| CN117660622B (zh) | 用于检测肺结节的甲基化分子标记物及其应用 | |
| KR102816628B1 (ko) | 대사증후군 특이적 후성유전 메틸화 마커 및 이의 용도 | |
| JP2004248508A5 (OSRAM) | ||
| CN116287222A (zh) | 甲状腺癌良恶性结节诊断的甲基化标志物及其应用 | |
| CN118048451A (zh) | 用于肝癌筛查的标志物、探针组合物及其应用 | |
| WO2025002157A1 (zh) | 用于检测食管癌的标记物及检测方法 | |
| CN119639889A (zh) | 基于胃癌标志物的检测方法和试剂盒 |